4.4 Article

Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance

期刊

BMC NEUROLOGY
卷 13, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1471-2377-13-16

关键词

Multiple sclerosis; Administrative data; Validation; Prevalence; Depression; Anxiety; Bipolar disorder; Schizophrenia

资金

  1. Canadian Institutes of Health Research
  2. Public Health Agency of Canada
  3. Manitoba Health Research Council
  4. Health Sciences Centre Foundation
  5. Multiple Sclerosis Society of Canada
  6. Multiple Sclerosis Scientific Foundation
  7. Rx & D Health Research Foundation
  8. Bayer Inc.
  9. Sanofi-Aventis
  10. Canadian Institutes of Health Research (CIHR)
  11. AstraZeneca
  12. Bayer
  13. Biogen-Idec Canada
  14. Heron Evidence Development Limited
  15. Hoffmann-La Roche
  16. MAPI Research Trust
  17. Novartis
  18. Serono Canada
  19. QualityMetric Incorporated
  20. Canadian International Development Agency
  21. CIHR
  22. Manitoba Health and Healthy Living
  23. Amgen
  24. Canadian Health Services Research Foundation
  25. Alberta Health Services
  26. SSHRC
  27. Canada Foundation for Innovation
  28. US National MS Society [RG 4202-A-2 (PI)]
  29. Canadian Institutes of Health Research [MOP] [190898 (PI), MOP-93646 (PI)]
  30. Michael Smith Foundation for Health Research
  31. Canada Research Chair program
  32. Bill & Melinda Gates Foundation
  33. United States Agency for International Development
  34. Alberta Innovates, Health Solutions
  35. Canadian Institutes for Health Research
  36. Institute of Health Economics
  37. Alberta Collaborative Research Grants Initiative
  38. Lundbeck
  39. Pfizer

向作者/读者索取更多资源

Background: While mental comorbidity is considered common in multiple sclerosis (MS), its impact is poorly defined; methods are needed to support studies of mental comorbidity. We validated and applied administrative case definitions for any mental comorbidities in MS. Methods: Using administrative health data we identified persons with MS and a matched general population cohort. Administrative case definitions for any mental comorbidity, any mood disorder, depression, anxiety, bipolar disorder and schizophrenia were developed and validated against medical records using a a kappa statistic (k). Using these definitions we estimated the prevalence of these comorbidities in the study populations. Results: Compared to medical records, administrative definitions showed moderate agreement for any mental comorbidity, mood disorders and depression (all k >= 0.49), fair agreement for anxiety (k = 0.23) and bipolar disorder (k = 0.30), and near perfect agreement for schizophrenia (k = 1.0). The age-standardized prevalence of all mental comorbidities was higher in the MS than in the general populations: depression (31.7% vs. 20.5%), anxiety (35.6% vs. 29.6%), and bipolar disorder (5.83% vs. 3.45%), except for schizophrenia (0.93% vs. 0.93%). Conclusions: Administrative data are a valid means of surveillance of mental comorbidity in MS. The prevalence of mental comorbidities, except schizophrenia, is increased in MS compared to the general population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据